Davita Inc vs Quantum Computing Inc — how do they compare? Davita Inc trades at $179.24 (market cap $11.29B), while Quantum Computing Inc trades at $7.39 (market cap $1.69B). The key difference: Davita Inc is far larger — about 6.7× Quantum Computing Inc's market cap, and Davita Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Quantum Computing Inc for 25 Days on average.
| DVA | QUBT | |
|---|---|---|
Market Cap | $11.29B | $1.69B |
Volume | 582,204 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $240.96 | $21.78 |
52-Week Low | $103.87 | $6.31 |
Typical Hold Time | 113 Days | 25 Days |
Enterprise Value | $24.01B | $753.24M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
QUBT trades at $7.39, down 3.02% today, amid a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 revenue of $5.6 million (Zacks Investment Research, 2026-09-08) but remains unprofitable with a net income margin of -152.45%. Recent news highlights the launch of Dirac-3S, scaling to 10,000 variables, with first shipments expected in Q4 2026 (PRNewsWire, 2026-10-01).
Analyst consensus is bullish with a $17.33 price target, but the stock faces significant risks from persistent losses, high cash burn, and competitive pressures. Investment appeal hinges on successful commercialization of quantum technology, though profitability remains distant. The company's $42.5 million backlog and liquidity provide some cushion against execution risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →